gut.bmj1d
Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis
Objective Bone marrow-derived myeloid cells accumulate in the liver as monocytes and macrophages during the progression of obesity-related non-alcoholic fatty liver disease (NAFLD) to steatohepatitis ...
gut.bmj1d
Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study
Correspondence to Julien Kirchgesner, Service de Gastroentérologie et Nutrition, Hôpital Saint-Antoine, Assistance Publique - Hôpitaux de Paris, 184 rue du faubourg Saint-Antoine, Paris 75012, France; ...
gut.bmj1d
Dietary fibres and IBS: translating functional characteristics to clinical value in the era of personalised medicine
Clinical guidelines in the use of fibre supplementation for patients with IBS provide one-size-fits-all advice, which has limited value. This narrative review addresses data and concepts around the ...
gut.bmj2d
Alternative treatments for type 2 diabetes and associated metabolic diseases: medical therapy or endoscopic duodenal mucosal remodelling?
Correspondence to Professor Jacques J G H M Bergman, Gastroenterology and Hepatology, Amsterdam UMC Location AMC, Amsterdam 1105 AZ, The Netherlands; j.j.bergman{at}amsterdamumc.nl Despite important ...
gut.bmj2d
Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease
Professor J P Galmiche, Centre de Recherche en Nutrition Humaine, CRI INSERM 95-08, CHU, Hôtel Dieu, Place A Ricordeau, 44035 Nantes cedex 01, France. Email:galmiche{at}easynet.fr BACKGROUND/AIM ...
gut.bmj3d
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic liver disease globally and is currently estimated to affect up to 38% of the global adult population. NAFLD is a ...
gut.bmj3d
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
1 Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN, USA 2 Division of Biostatistics, Mayo Clinic and Foundation, Rochester, MN, USA Correspondence to: Dr E V ...
gut.bmj3d
Faecal metabolome and its determinants in inflammatory bowel disease
Objective Inflammatory bowel disease (IBD) is a multifactorial immune-mediated inflammatory disease of the intestine, comprising Crohn’s disease and ulcerative colitis. By characterising metabolites ...
gut.bmj6d
Irritable bowel syndrome: treatment based on pathophysiology and biomarkers
Objective To appraise the evidence that pathophysiological mechanisms and individualised treatment directed at those mechanisms provide an alternative approach to the treatment of patients with ...
gut.bmj6d
Microbiota-induced S100A11-RAGE axis underlies immune evasion in right-sided colon adenomas and is a therapeutic target to boost anti-PD1 efficacy
2 Key Laboratory of Human Microbiome and Chronic Diseases (Sun Yat-sen University), Ministry of Education, Guangzhou, China Background Tumourigenesis in right-sided and left-sided colons demonstrated ...
gut.bmj15d
Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control
Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...
gut.bmj16d
Detection of large flat colorectal lesions by artificial intelligence: a persistent weakness and blind spot
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...